Chemotherapy was administered every 3 weeks for six cycles, and bevacizumab was administered every 3 weeks until disease progression was evident or toxic effects were intolerable.

• 434位患者接受紫杉醇-卡铂-贝伐单抗联合化疗（1次/3周,持续化疗直至患者出现明显的疾病进展状况？或对毒性效应不能耐受）。